Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Breast Cancer | Research

Efficacy and safety analysis of hypofractionated and conventional fractionated radiotherapy in postoperative breast cancer patients

Authors: Yongkai Lu, Beina Hui, Di Yang, Yi Li, Binglin Li, Luping Zhou, Lei Xu, Fengwen Tang, Wei Wang, Ruijuan Chen, Dongli Zhao

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Objectives

In this meta-analysis, we conducted a comparative analysis of the safety and efficacy of hypofractionated and conventional fractionated radiotherapy in individuals who had undergone surgery for breast cancer.

Methods

This study involved a systematic and independent review of relevant research articles published in reputable databases such as PubMed, Embase, Cochrane Library, and Web of Science. Two investigators conducted the review, which included studies published up to January 3, 2023. The quality of the eligible studies was evaluated and data were extracted using Review Manager software 5.4 (RevMan 5.4) to calculate odds ratios (ORs) and 95% confidence intervals (CIs).

Results

The analysis comprised 35 studies and encompassed a collective sample of 18,246 individuals diagnosed with breast cancer. We did not find a statistically significant disparity in efficacy between conventional fractionated (CF) radiotherapy and hypofractionated (HF) radiotherapy regarding local recurrence (LR; OR = 0.91, 95% CI: 0.76–1.09, P = 0.30), disease-free survival (DFS; OR = 1.20, 95% CI: 1.01–1.42, P = 0.03), and overall survival (OS; OR = 1.08, 95% CI: 0.93–1.26, P = 0.28). Concerning safety, there was no significant difference between the HF and CF regimens in terms of breast pain, breast atrophy, lymphedema, pneumonia, pulmonary fibrosis, telangiectasia, and cardiotoxicity. However, the HF regimen resulted in lower skin toxicity (OR = 0.43, 95% CI: 0.33—0.55, P < 0.01) and improved patient fatigue outcomes (OR = 0.73, 95% CI: 0.60 – 0.88, P < 0.01).

Conclusions

Although there is no substantial difference in LR, DFS, OS, or many other side effects between the HF and CF regimens, the HF regimen reduces skin toxicity and relieves patient fatigue. If these two issues need to be addressed in clinical situations, the HF regimen may be a superior alternative to conventional radiotherapy in postoperative breast cancer patients.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.PubMedCrossRef
3.
Singh MN, Kinhikar RA, Agarwal JP, Laskar SG: Principles and Practice of Radiation Oncology. In: Fundamentals in Gynaecologic Malignancy. edn. Edited by Kataki AC, Barmon D. Singapore: Springer Nature Singapore; 2022: 99–117.
4.
Bekelman JE, Sylwestrzak G, Barron J, Liu J, Epstein AJ, Freedman G, Malin J, Emanuel EJ. Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008–2013. JAMA. 2014;312(23):2542–50.PubMedPubMedCentralCrossRef
5.
Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, Shelley W, Grimard L, Bowen J, Lukka H, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–20.PubMedCrossRef
6.
Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bentzen SM, Bliss JM, Brown J, Dewar JA, Dobbs HJ, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098–107.PubMedCrossRef
7.
Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, et al. The UK standardisation of breast radiotherapy (start) trial a of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9(4):331–41.PubMedCrossRef
8.
Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ, Hopwood P, Lawton PA, Magee BJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086–94.PubMedCrossRef
9.
Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(8):1194–220.PubMedCrossRef
10.
Murray Brunt A, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, Chan C, Churn M, Cleator S, Coles CE, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395(10237):1613–26.PubMedPubMedCentralCrossRef
11.
Machiels M, Weytjens R, Bauwens W, Vingerhoed W, Billiet C, Huget P, Verellen D, Dirix P, Meijnders P, Poortmans P, et al. Accelerated adaptation of ultrahypofractionated radiation therapy for breast cancer at the time of the COVID-19 pandemic. Clin Oncol (R Coll Radiol). 2021;33(3):e166–71.PubMedCrossRef
12.
Verbanck S, Van Parijs H, Schuermans D, Vinh-Hung V, Storme G, Fontaine C, De Ridder M, Verellen D, Vanderhelst E, Hanon S. Lung restriction in patients with breast cancer after hypofractionated and conventional radiation therapy: a 10-year follow-up. Int J Radiat Oncol Biol Phys. 2022;113(3):561–9.PubMedCrossRef
13.
Xie J, Xu F, Zhao Y, Cai G, Lin X, Zhu Q, Lin Q, Yao Y, Xu C, Cai R, et al. Hypofractionated versus conventional intensity-modulated radiation irradiation (HARVEST-adjuvant): study protocol for a randomised non-inferior multicentre phase III trial. BMJ Open. 2022;12(9):e062034.PubMedPubMedCentralCrossRef
14.
Chua BH, Link EK, Kunkler IH, Whelan TJ, Westenberg AH, Gruber G, Bryant G, Ahern V, Purohit K, Graham PH, et al. Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study. Lancet. 2022;400(10350):431–40.PubMedCrossRef
15.
Kim D-Y, Park E, Heo CY, Jin US, Kim EK, Han W, Shin KH, Kim IA. Influence of hypofractionated versus conventional fractionated postmastectomy radiation therapy in breast cancer patients with reconstruction. Int J Radiat Oncol Biol Phys. 2022;112(2):445–56.PubMedCrossRef
16.
Wang S-L, Fang H, Hu C, Song Y-W, Wang W-H, Jin J, Liu Y-P, Ren H, Liu J, Li G-F, et al. Hypofractionated versus conventional fractionated radiotherapy after breast-conserving surgery in the modern treatment era: a multicenter, randomized controlled trial from China. J Clin Oncol. 2020;38(31):3604-+.PubMedCrossRef
17.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE: The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. Bmj-British Med J. 2020;2021:372.
18.
Shuster J. Review: Cochrane handbook for systematic reviews for interventions, Version 5.1.0, published 3/2011. Julian P.T. Higgins and Sally Green, Editors. Res Synth Methods. 2011;2:126–30.CrossRef
19.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.PubMedCrossRef
20.
Oremus M, Wolfson C, Perrault A, Demers L, Momoli F, Moride Y. Interrater reliability of the modified jadad quality scale for systematic reviews of Alzheimer’s disease drug trials. Dement Geriatr Cogn Disord. 2001;12(3):232–6.PubMedCrossRef
21.
22.
23.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMed
24.
Oar AJ, Boxer MM, Papadatos G, Delaney GP, Phan P, Descallar J, Duggan K, Tran K, Yap ML. Hypofractionated versus conventionally fractionated radiotherapy for ductal carcinoma in situ (DCIS) of the breast. J Med Imaging Radiat Oncol. 2016;60(3):407–13.PubMedCrossRef
25.
Offersen BV, Alsner J, Nielsen HM, Jakobsen EH, Nielsen MH, Krause M, Stenbygaard L, Mjaaland I, Schreiber A, Kasti UM, et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO Trial. J Clin Oncol. 2020;38(31):3615–25.PubMedCrossRef
26.
Laughlin BS, Bhangoo RS, Thorpe CS, Golafshar MA, DeWees TA, Anderson JD, Vern-Gross TZ, McGee LA, Wong WW, Halyard MY, et al. Patient-reported outcomes for patients with breast cancer undergoing radiotherapy: a single-center registry experience. Front Oncol. 2022;12:920739.PubMedPubMedCentralCrossRef
27.
Chadha M, Vongtama D, Friedmann P, Parris C, Boolbol SK, Woode R, Harrison LB. Comparative acute toxicity from whole breast irradiation using 3-week accelerated schedule with concomitant boost and the 6.5-week conventional schedule with sequential boost for early-stage breast cancer. Clin Breast Cancer. 2012;12(1):57–62.PubMedCrossRef
28.
Herbert C, Nichol A, Olivotto I, Weir L, Woods R, Speers C, Truong P, Tyldesley S. The impact of hypofractionated whole breast radiotherapy on local relapse in patients with grade 3 early breast cancer: a population-based cohort study. Int J Radiat Oncol Biol Phys. 2012;82(5):2086–92.PubMedCrossRef
29.
Chuang WK, Cheng S-C, Hung CF, Huang TT, Jen CW, Yen JH, Tsai YC: Comparison between the use of hypofractionated and conventionally fractionated radiotherapy in early breast cancer: a single-center real-world study in Taiwan. Journal of the Formosan Medical Association / Taiwan yi zhi 2022.
30.
Fehlauer F, Tribius S, Alberti W, Rades D. Late effects and cosmetic results of conventional versus hypofractionated irradiation in breast-conserving therapy. Strahlenther Onkol. 2005;181(10):625–31.PubMedCrossRef
31.
De Felice F, Ranalli T, Musio D, Lisi R, Rea F, Caiazzo R, Tombolini V. Relation between hypofractionated radiotherapy, toxicity and outcome in early breast cancer. Breast J. 2017;23(5):563–8.PubMedCrossRef
32.
Tortorelli G, Di Murro L, Barbarino R, Cicchetti S, di Cristino D, Falco MD, Fedele D, Ingrosso G, Janniello D, Morelli P, et al. Standard or hypofractionated radiotherapy in the postoperative treatment of breast cancer: a retrospective analysis of acute skin toxicity and dose inhomogeneities. Bmc Cancer. 2013;13:1–9.CrossRef
33.
Eldeeb H, Awad I, Elhanafy O. Hypofractionation in post-mastectomy breast cancer patients: seven-year follow-up. Med Oncol. 2012;29(4):2570–6.PubMedCrossRef
34.
Hou HL, Song YC, Li RY, Zhu L, Zhao LJ, Yuan ZY, You JQ, Chen ZJ, Wang P. Similar outcomes of standard radiotherapy and hypofractionated radiotherapy following breast-conserving surgery. Med Sci Monit. 2015;21:2251–6.PubMedPubMedCentralCrossRef
35.
Arsenault J, Parpia S, Goldberg M, Rakovitch E, Reiter H, Doherty M, Lukka H, Sussman J, Wright J, Julian J, et al. Acute toxicity and quality of life of hypofractionated radiation therapy for breast cancer. Int J Radiat Oncol Biol Phys. 2020;107(5):943–8.PubMedCrossRef
36.
King MT, Link EK, Whelan TJ, Olivotto IA, Kunkler I, Westenberg AH, Gruber G, Schofield P, Chua BH, Investig BTT. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(5):685–98.PubMedCrossRef
37.
Saksornchai K, Jaruthien T, Nantavithya C, Shotelersuk K, Rojpornpradit P. Long-term results of hypofractionation with concomitant boost in patients with early breast cancer: a prospective study. Plos One. 2021;16(10):e0258186.PubMedPubMedCentralCrossRef
38.
Kumar SV, Baskar P, Sunderesan C, Kumar HPR. Comparison of radiation-induced toxicities, treatment feasibility in conventional versus hypo-fractionated protocols of post mastectomy radiotherapy. J Evol Med Dental Sci Jemds. 2018;7(6):767–70.
39.
Lee SW, Kim YJ, Shin KH, Kim K, Chie EK, Han W, Im SA, Jung SY, Lee KS, Lee ES. A Comparative study of daily 3-Gy hypofractionated and 1.8-gy conventional breast irradiation in early-stage breast cancer. Med. 2016;95(19):e3320.CrossRef
40.
Schmeel LC, Koch D, Schmeel FC, Röhner F, Schoroth F, Bücheler BM, Mahlmann B, Leitzen C, Schüller H, Tschirner S, et al. Acute radiation-induced skin toxicity in hypofractionated vs. conventional whole-breast irradiation: an objective, randomized multicenter assessment using spectrophotometry. Radiother Oncol. 2020;146:172–9.PubMedCrossRef
41.
Maiti S, Meyur S, Mandal BC, Shenoi LR, Biswas S, Basu S. Comparison of conventional and hypofractionated radiation after mastectomy in locally advanced breast cancer: a prospective randomised study on dosimetric evaluation and treatment outcome. J Radiother Pract. 2021;20(1):30–8.CrossRef
42.
Mishra R, Khurana R, Mishra H, Rastogi M, Hadi R. Retrospective analysis of efficacy and toxicity of hypo-fractionated radiotherapy in breast carcinoma. J Clin Diagnostic Res. 2016;10(8):XC01–3.
43.
Rastogi K, Jain S, Bhatnagar AR, Bhaskar S, Gupta S, Sharma N. A comparative study of hypofractionated and conventional radiotherapy in postmastectomy breast cancer patients. Asia Pac J Oncol Nurs. 2018;5(1):107–13.PubMedPubMedCentralCrossRef
44.
Jagsi R, Griffith KA, Boike TP, Walker E, Nurushev T, Grills IS, Moran JM, Feng M, Hayman J, Pierce LJ. Differences in the acute toxic effects of breast radiotherapy by fractionation schedule comparative analysis of physician-assessed and patient-reported outcomes in a large multicenter cohort. JAMA Oncol. 2015;1(7):918–30.PubMedCrossRef
45.
Kumar S, Singh S, Prasad SN, Korde M, Elhence A, Shakya V. A prospective study to compare hypo-fractionated radiotherapy versus conventional radiotherapy in carcinoma breast. Int J Pharm Sci Res. 2019;10(4):2071–8.
46.
Shaitelman SF, Schlembach PJ, Arzu I, Ballo M, Bloom ES, Buchholz D, Chronowski GM, Dvorak T, Grade E, Hoffman KE, et al. Acute and short-term toxic effects of conventionally fractionated vs hypofractionated whole-breast irradiation: a randomized clinical trial. JAMA Oncol. 2015;1(7):931–41.PubMedPubMedCentralCrossRef
47.
Shaitelman SF, Lei X, Thompson A, Schlembach P, Bloom ES, Arzu IY, Buchholz D, Chronowski G, Dvorak T, Grade E, et al. Three-year outcomes with hypofractionated versus conventionally fractionated whole-breast irradiation: results of a randomized, noninferiority clinical trial. J Clin Oncol. 2018;36(35):3495–503.PubMedCentralCrossRef
48.
Osako T, Oguchi M, Kumada M, Nemoto K, Iwase T, Yamashita T. Acute radiation dermatitis and pneumonitis in Japanese breast cancer patients with whole breast hypofractionated radiotherapy compared to conventional radiotherapy. Jpn J Clin Oncol. 2008;38(5):334–8.PubMedCrossRef
49.
Kouloulias V, Mosa E, Zygogianni A, Kypraiou E, Georgakopoulos J, Platoni K, Antypas C, Kyrgias G, Tolia M, Papadimitriou C, et al. A retrospective analysis of toxicity and efficacy for 2 hypofractionated irradiation schedules versus a conventional one for post-mastectomy adjuvant radiotherapy in breast cancer. Breast Care. 2016;11(5):328–32.PubMedPubMedCentralCrossRef
50.
Rudat V, Nour A, AbouGhaida S, Alaradi A. Impact of hypofractionation and tangential beam IMRT on the acute skin reaction in adjuvant breast cancer radiotherapy. Radiation Oncol. 2016;11:e3320.CrossRef
51.
Wang SL, Fang H, Song YW, Wang WH, Hu C, Liu YP, Jin J, Liu XF, Yu ZH, Ren H, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2019;20(3):352–60.PubMedCrossRef
52.
Butler-Xu YS, Marietta M, Zahra A, TenNapel M, Mitchell M. The effect of breast volume on toxicity using hypofractionated regimens for early stage breast cancer for patients. Adv Radiat Oncol. 2019;4(2):261–7.PubMedCrossRef
53.
Zhao S, Liu Y, Huang F, Chen X, Cao X, Yu J. The long-term outcome of adjuvant hypofractionated radiotherapy and conventional fractionated radiotherapy after breast-conserving surgery for early breast cancer: a prospective analysis of 107 cases. J Thorac Dis. 2017;9(10):3840–50.PubMedPubMedCentralCrossRef
54.
Weng JK, Lei X, Schlembach P, Bloom ES, Shaitelman SF, Arzu IY, Chronowski G, Dvorak T, Grade E, Hoffman K, et al. Five-year longitudinal analysis of patient-reported outcomes and cosmesis in a randomized trial of conventionally fractionated versus hypofractionated whole-breast irradiation. Int J Radiat Oncol Biol Phys. 2021;111(2):360–70.PubMedPubMedCentralCrossRef
55.
Jiang Z, Song E, Geng C, Pan Y, Wang X, Wang X: Chinese Society of Clinical Oncology (CSCO) Breast Cancer Treatment Guidelines 2022. In.; 2022.
56.
Smith BD, Bellon JR, Blitzblau R, Freedman G, Haffty B, Hahn C, Halberg F, Hoffman K, Horst K, Moran J, et al. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol. 2018;8(3):145–52.PubMedCrossRef
57.
Gu L, Dai W, Fu R, Lu H, Shen J, Shi Y, Zhang M, Jiang K, Wu F. Comparing hypofractionated with conventional fractionated radiotherapy after breast-conserving surgery for early breast cancer: a meta-analysis of randomized controlled trials. Front Oncol. 2021;11:753209.PubMedPubMedCentralCrossRef
58.
Zhou Z-R, Mei X, Chen X-X, Yang Z-Z, Hou J, Zhang L, Yu X-L, Guo X-M. Systematic review and meta-analysis comparing hypofractionated with conventional fraction radiotherapy in treatment of early breast cancer. Surg Oncol. 2015;24(3):200–11.PubMedCrossRef
59.
Andrade TRM, Fonseca MCM, Segreto HRC, Segreto RA, Martella E, Nazário ACP. Meta-analysis of long-term efficacy and safety of hypofractionated radiotherapy in the treatment of early breast cancer. The Breast. 2019;48:24–31.PubMedCrossRef
60.
Jones B, Dale RG, Deehan C, Hopkins KI, Morgan DA. The role of biologically effective dose (BED) in clinical oncology. Clin Oncol (R Coll Radiol). 2001;13(2):71–81.PubMed
61.
Nahum AE. The radiobiology of hypofractionation. Clin Oncol. 2015;27(5):260–9.CrossRef
62.
Tutt A, Yarnold J. Radiobiology of breast cancer. Clin Oncol. 2006;18(3):166–78.CrossRef
63.
Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J, Haviland J, Bentzen S, Owen R. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol. 2005;75(1):9–17.PubMedCrossRef
64.
Lundstedt D, Gustafsson M, Steineck G, Malmström P, Alsadius D, Sundberg A, Wilderäng U, Holmberg E, Johansson KA, Karlsson P. Risk factors of developing long-lasting breast pain after breast cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83(1):71–8.PubMedCrossRef
65.
Deantonio L, Gambaro G, Beldì D, Masini L, Tunesi S, Magnani C, Krengli M. Hypofractionated radiotherapy after conservative surgery for breast cancer: analysis of acute and late toxicity. Radiat Oncol. 2010;5:112.PubMedPubMedCentralCrossRef
66.
Brunt AM, Wheatley D, Yarnold J, Somaiah N, Kelly S, Harnett A, Coles C, Goodman A, Bahl A, Churn M, et al. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiother Oncol. 2016;120(1):114–8.PubMedPubMedCentralCrossRef
67.
68.
Parks RM, Cheung KL. Axillary reverse mapping in N0 patients requiring sentinel lymph node biopsy - a systematic review of the literature and necessity of a randomised study. Breast. 2017;33:57–70.PubMedCrossRef
69.
Abid SH, Malhotra V, Perry MC. Radiation-induced and chemotherapy-induced pulmonary injury. Curr Opin Oncol. 2001;13(4):242–8.PubMedCrossRef
70.
Bentzen SM. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer. 2006;6(9):702–13.PubMedCrossRef
71.
Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–98.PubMedCrossRef
72.
Lu Y, Yang D, Zhang X, Teng Y, Yuan W, Zhang Y, He R, Tang F, Pang J, Han B, et al. Comparison of deep inspiration breath hold versus free breathing in radiotherapy for left sided breast cancer. Front Oncol. 2022;12:845037.PubMedPubMedCentralCrossRef
73.
Hauth F, De-Colle C, Weidner N, Heinrich V, Zips D, Gani C. Quality of life and fatigue before and after radiotherapy in breast cancer patients. Strahlenther Onkol. 2021;197(4):281–7.PubMedCrossRef
Metadata
Title
Efficacy and safety analysis of hypofractionated and conventional fractionated radiotherapy in postoperative breast cancer patients
Authors
Yongkai Lu
Beina Hui
Di Yang
Yi Li
Binglin Li
Luping Zhou
Lei Xu
Fengwen Tang
Wei Wang
Ruijuan Chen
Dongli Zhao
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-11918-2

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Metabolic difference between patient-derived xenograft model of pancreatic ductal adenocarcinoma and corresponding primary tumor

Research

Comparing the efficacy of a multi-dimensional breast cancer rehabilitation programme versus a home-based exercise programme during adjuvant cancer treatment

Research

Prognostic marker CD27 and its micro-environmental in multiple myeloma

Research

Validation of primary and outcome data quality in a Swedish population-based breast cancer quality registry

Research

Heterogeneous changes in gut and tumor microbiota in patients with pancreatic cancer: insights from clinical evidence

Research

Modulating DNA damage response in uveal melanoma through embryonic stem cell microenvironment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits